MX2009004170A - Materiales y metodos para inmunoglicoproteinas mejoradas. - Google Patents

Materiales y metodos para inmunoglicoproteinas mejoradas.

Info

Publication number
MX2009004170A
MX2009004170A MX2009004170A MX2009004170A MX2009004170A MX 2009004170 A MX2009004170 A MX 2009004170A MX 2009004170 A MX2009004170 A MX 2009004170A MX 2009004170 A MX2009004170 A MX 2009004170A MX 2009004170 A MX2009004170 A MX 2009004170A
Authority
MX
Mexico
Prior art keywords
castanospermine
dependent cytotoxicity
increasing antibody
immunoglycoproteins
antibody
Prior art date
Application number
MX2009004170A
Other languages
English (en)
Inventor
Baum Peter Robert
Thompson Peter Armstrong
Espling Erik Stephen
Original Assignee
Trubion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trubion Pharmaceuticals Inc filed Critical Trubion Pharmaceuticals Inc
Publication of MX2009004170A publication Critical patent/MX2009004170A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las inmunoglicoproteínas incluyen anticuerpos, con una ADCC (citotoxicidad dependiente de anticuerpos) mejorada y se proveen patrones de glicosilación alterados. También se proporcionan métodos de cultivo celular y los medios para producir tales inmunoglicoproteínas y usos terapéuticos de tales inmunoglicoproteínas.
MX2009004170A 2006-10-24 2007-10-24 Materiales y metodos para inmunoglicoproteinas mejoradas. MX2009004170A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85394406P 2006-10-24 2006-10-24
PCT/US2007/082343 WO2008052030A2 (en) 2006-10-24 2007-10-24 A method for increasing antibody-dependent cytotoxicity with castanospermine

Publications (1)

Publication Number Publication Date
MX2009004170A true MX2009004170A (es) 2009-06-26

Family

ID=39204867

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004170A MX2009004170A (es) 2006-10-24 2007-10-24 Materiales y metodos para inmunoglicoproteinas mejoradas.

Country Status (9)

Country Link
US (2) US20100150948A1 (es)
EP (1) EP2076538A2 (es)
JP (1) JP2010507394A (es)
CN (1) CN101646688A (es)
AU (1) AU2007308983B2 (es)
BR (1) BRPI0717601A2 (es)
CA (1) CA2663536A1 (es)
MX (1) MX2009004170A (es)
WO (1) WO2008052030A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP2295080A3 (en) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US7846434B2 (en) * 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
EP3281955A1 (en) 2008-10-02 2018-02-14 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
JP2014501097A (ja) * 2009-07-06 2014-01-20 アルナイラム ファーマシューティカルズ， インコーポレイテッド 生物由来物質の産生を高めるための組成物及び方法
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
MX338932B (es) 2010-03-12 2016-05-06 Immunogen Inc Moleculas de union cd37 y sus inmunoconjugados.
EP3513794A3 (en) 2010-08-05 2019-10-16 Seattle Genetics, Inc. Fucose analogs for inhibition of protein fucosylation in vivo
CN105999293B (zh) 2011-04-01 2019-07-23 德彪发姆国际有限公司 Cd37结合分子及其免疫缀合物
US10350228B2 (en) 2012-08-23 2019-07-16 Seattle Genetics, Inc. Treatment of sickle cell disease and inflammatory conditions
ES3030960T3 (en) * 2013-10-31 2025-07-02 Amgen Inc Use of monensin to regulate glycosylation of recombinant proteins
UA125496C2 (uk) 2015-06-08 2022-04-13 Дебіофарм Інтернаціонал, С.А. Спосіб лікування пацієнта з в-клітинним раком імунокон’югатом, який зв’язується з cd37 разом з антитілом, що зв'язується з cd20
AU2016316758B2 (en) 2015-08-28 2023-02-02 Debiopharm International, S.A. Antibodies and assays for detection of CD37
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
WO2018083633A1 (en) 2016-11-02 2018-05-11 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
BR112019008223A2 (pt) 2016-11-03 2019-07-16 Bristol-Myers Squibb Company anticorpos anti-ctla-4 ativáveis e usos dos mesmos
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CN119639849A (zh) 2018-03-26 2025-03-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
CA3101790A1 (en) 2018-05-30 2019-12-05 Debiopharm International, S.A. Anti-cd37 immunoconjugate dosing regimens
SG11202106481SA (en) * 2018-12-19 2021-07-29 Seagen Inc Controlled fucosylation of antibodies
WO2025245176A1 (en) 2024-05-22 2025-11-27 Bristol-Myers Squibb Company Multispecific antibody constructs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
WO1992016622A1 (en) * 1991-03-12 1992-10-01 Biogen, Inc. Cd2-binding domain of lymphocyte function associated antigen 3
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7560534B2 (en) * 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
IL155977A0 (en) * 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7371849B2 (en) * 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
KR100988949B1 (ko) * 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
ATE435239T1 (de) * 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
JP4767857B2 (ja) * 2003-09-30 2011-09-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンゾイミダゾール化合物
WO2005042768A2 (en) * 2003-11-03 2005-05-12 Centocor, Inc. Method for maintaining low shear in a bioprocessing system
EP2295080A3 (en) * 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
ATE536373T1 (de) * 2005-10-21 2011-12-15 Genzyme Corp Therapiemittel auf antikörperbasis mit erhöhter adcc-aktivität

Also Published As

Publication number Publication date
US20100150948A1 (en) 2010-06-17
EP2076538A2 (en) 2009-07-08
US20130280240A1 (en) 2013-10-24
AU2007308983A1 (en) 2008-05-02
WO2008052030A3 (en) 2008-06-12
WO2008052030A2 (en) 2008-05-02
CA2663536A1 (en) 2008-05-02
JP2010507394A (ja) 2010-03-11
AU2007308983B2 (en) 2012-12-06
BRPI0717601A2 (pt) 2013-10-22
CN101646688A (zh) 2010-02-10

Similar Documents

Publication Publication Date Title
WO2008052030A3 (en) A method for increasing antibody-dependent cytotoxicity with castanospermine
WO2009126858A3 (en) Materials and methods for improved immunoglycoproteins
EP2007386A4 (en) CAMPTOTHECIN ANALOGUE HAVING A NEW LACTONE STABLE RETURNED "RETURNED" CORE AND METHODS FOR PREPARING AND USING SAME
EP2068389B8 (en) Method for producing separator for fuel cell, separator for fuel cell, and fuel cell
MX2007008506A (es) Metodos y productos para genotipificacion in vitro.
EP1901127A4 (en) BINDER RESIN FOR TONER, TONER AND PROCESS FOR PREPARING THE BINDER RESIN FOR TONER
MX300732B (es) Celulasas, acidos nucleicos que las codifican y metodos para hacerlas y usarlas.
EP2094844A4 (en) IMPROVED BUTANOL PRODUCING MICROORGANISMS AND METHOD FOR THE PRODUCTION OF BUTANOL THEREWITH
IL180125A0 (en) Methods for producing biodiesel
IL197459A (en) Manned proteins, including antibodies, and methods for their preparation
EP2028172A4 (en) PROCESS FOR PRODUCING 1,3,3,3-TETRAFLUOROPROPENE
WO2009126350A3 (en) Methods and compositions for targeting k63-linked polyubiquitin
WO2007011742A3 (en) Cigs photovoltaic cells
AP2290A (en) Method of producing a booklet, data page produced by this method and booklet by the method.
TWI318298B (en) Method for manufacturing a conductive contacter holder, and the conductive contacter holder
EP2119518A4 (en) FINE SILVER POWDER
EP1911538A4 (en) EDGE REPLACEMENT CUTTING HEAD AND METHOD FOR PRODUCING THE SAME
MX2007004642A (es) Combinaciones polimericas para producir peliculas con un numero reducido de defectos.
EP2014824B8 (en) Reinforcing cord, method for producing the same, and product using the reinforcing cord
MX280092B (es) Proceso para producir un compuesto de 5 - hidroxi - 4 - tiometilpirazol.
WO2008086228A3 (en) Arrays and methods for guided cell patterning
WO2006044754A3 (en) Process for preparing telmisartan
SG129313A1 (en) Carbon black, method for producing the same, and its use
PL1985176T3 (pl) Zabarwiona żyłka wędkarska i proces jej wytwarzania
PT2225314T (pt) Silicones-autoadesivos, método de fabrico, complexos que os utilizam e aplicações

Legal Events

Date Code Title Description
FG Grant or registration